| Product name | Linezolid |
| CAS Number | 165800-03-3 |
| Synonyms | LinezolidandInterMediate;N-{[(5S)-3-[3-fluoro-4-(Morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]Methyl}acetaMide;(S)-N-((3-(3-fluoro-4-Morpholinophenyl)-2-oxooxazolidin-5-yl)Methyl)acetaMide;(S)-N-[[3-(3-Fluoro-4-morpholinophenyl)-2-oxChemicalbooko-5-oxazolidinyl]methyl]acetamide;Linezolid-13C-d3;Acetamide,N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-(9CI);Acetamide,N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-,(S)-;PNU100766 |
| Molecular formula | C16H20FN3O4 |
| Molecular weight | 337.35 |
| Purity | 99% |
| Appearance | White Powder |
| EINECS number | 605-416-1 |
Linezolid is supplied as a ready-to-use sterile isotonic solution for intravenous infusion. Each mL contains 2 mg of linezolid. Inactive ingredients are sodium citrate, citric acid, and dextrose in an aqueous vehicle for intravenous administration. The sodium (Na+) content is 0.38 mg/mL (5 mEq per 300-mL bag; 3.3 mEq per 200-mL bag; and 1.7 mEq per 100-mL bag).
Linezolid CAS 165800-03-3 ApplicationFor the treatment of infections caused by Gram-positive cocci, the complex infections of skin and soft tissue, uncomplicated infections of skin and soft tissue, treatment ofinfections caused by vancomycin-resistant Enterococcus faecium.
